|
EP0932694A2
(en)
|
1996-09-11 |
1999-08-04 |
THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Aav4 vector and uses thereof
|
|
DE69939169D1
(de)
|
1998-05-28 |
2008-09-04 |
Us Gov Health & Human Serv |
Aav5 vektoren und deren verwendung
|
|
WO2004060278A2
(en)
|
2002-12-06 |
2004-07-22 |
Isis Pharmaceuticals, Inc. |
Methods for rapid identification of pathogens in humans and animals
|
|
US7226739B2
(en)
|
2001-03-02 |
2007-06-05 |
Isis Pharmaceuticals, Inc |
Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
|
|
US7666588B2
(en)
|
2001-03-02 |
2010-02-23 |
Ibis Biosciences, Inc. |
Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
|
|
US7718354B2
(en)
|
2001-03-02 |
2010-05-18 |
Ibis Biosciences, Inc. |
Methods for rapid identification of pathogens in humans and animals
|
|
US20040121309A1
(en)
|
2002-12-06 |
2004-06-24 |
Ecker David J. |
Methods for rapid detection and identification of bioagents in blood, bodily fluids, and bodily tissues
|
|
US20030027135A1
(en)
|
2001-03-02 |
2003-02-06 |
Ecker David J. |
Method for rapid detection and identification of bioagents
|
|
US7217510B2
(en)
|
2001-06-26 |
2007-05-15 |
Isis Pharmaceuticals, Inc. |
Methods for providing bacterial bioagent characterizing information
|
|
US8073627B2
(en)
|
2001-06-26 |
2011-12-06 |
Ibis Biosciences, Inc. |
System for indentification of pathogens
|
|
CN103555677B
(zh)
|
2001-11-13 |
2018-01-30 |
宾夕法尼亚大学托管会 |
检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
|
|
PT2573170T
(pt)
*
|
2001-12-17 |
2018-03-26 |
Univ Pennsylvania |
Sequências de um vírus adenoassociado (aav) de serotipo 9, vetor contendo as mesmas, e suas utilizações
|
|
WO2003052051A2
(en)
|
2001-12-17 |
2003-06-26 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (aav) serotype 8 sequences
|
|
CA2426283C
(en)
|
2002-04-29 |
2006-06-27 |
The Trustees Of The University Of Pennsylvania |
Method for direct rescue and amplification of integrated viruses from cellular dna of tissues
|
|
US7419817B2
(en)
|
2002-05-17 |
2008-09-02 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. |
Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
|
|
AU2003265855A1
(en)
*
|
2002-08-28 |
2004-03-19 |
University Of Florida |
Modified aav
|
|
US8046171B2
(en)
|
2003-04-18 |
2011-10-25 |
Ibis Biosciences, Inc. |
Methods and apparatus for genetic evaluation
|
|
US8057993B2
(en)
|
2003-04-26 |
2011-11-15 |
Ibis Biosciences, Inc. |
Methods for identification of coronaviruses
|
|
US8158354B2
(en)
|
2003-05-13 |
2012-04-17 |
Ibis Biosciences, Inc. |
Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
|
|
US7964343B2
(en)
|
2003-05-13 |
2011-06-21 |
Ibis Biosciences, Inc. |
Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
|
|
WO2005017101A2
(en)
|
2003-05-19 |
2005-02-24 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH |
Avian adenoassociated virus (aaav) and uses thereof
|
|
JP2007524386A
(ja)
|
2003-06-19 |
2007-08-30 |
アビジェン， インコーポレイテッド |
減少した免疫反応性を有するａａｖビリオン、およびその使用
|
|
US9233131B2
(en)
|
2003-06-30 |
2016-01-12 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
|
AU2010201278B2
(en)
*
|
2003-09-01 |
2012-11-15 |
Academisch Medisch Centrum |
AAV vectors for in vivo gene therapy of rheumatoid arthritis
|
|
US8529885B2
(en)
*
|
2003-09-01 |
2013-09-10 |
Academisch Medisch Centrum |
AAV vectors for in vivo gene therapy of rheumatoid arthritis
|
|
US8097416B2
(en)
|
2003-09-11 |
2012-01-17 |
Ibis Biosciences, Inc. |
Methods for identification of sepsis-causing bacteria
|
|
US8546082B2
(en)
|
2003-09-11 |
2013-10-01 |
Ibis Biosciences, Inc. |
Methods for identification of sepsis-causing bacteria
|
|
US8288523B2
(en)
|
2003-09-11 |
2012-10-16 |
Ibis Biosciences, Inc. |
Compositions for use in identification of bacteria
|
|
DK3211085T3
(da)
*
|
2003-09-30 |
2021-06-21 |
Univ Pennsylvania |
Klader af adeno-associeret virus (aav), sekvenser, vektorer indeholdende disse og anvendelser deraf
|
|
AU2011250849B2
(en)
*
|
2003-09-30 |
2013-09-12 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor
|
|
WO2005056807A2
(en)
|
2003-12-04 |
2005-06-23 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health |
Bovine adeno-associated viral (baav) vector and uses thereof
|
|
US7666592B2
(en)
|
2004-02-18 |
2010-02-23 |
Ibis Biosciences, Inc. |
Methods for concurrent identification and quantification of an unknown bioagent
|
|
US8119336B2
(en)
|
2004-03-03 |
2012-02-21 |
Ibis Biosciences, Inc. |
Compositions for use in identification of alphaviruses
|
|
EP1742657B1
(en)
|
2004-04-28 |
2013-11-06 |
The Trustees of The University of Pennsylvania |
Immunization regimen with e4-deleted adenovirus prime and e1-deleted adenovirus boost
|
|
ES2361000T3
(es)
|
2004-04-28 |
2011-06-13 |
The Trustees Of The University Of Pennsylvania |
Suministro secuencial de moléculas inmunogénicas mediante administraciones de un adenovirus y de un virus adeno-asociado.
|
|
EP2458619B1
(en)
|
2004-05-24 |
2017-08-02 |
Ibis Biosciences, Inc. |
Mass spectrometry with selective ion filtration by digital thresholding
|
|
US20050266411A1
(en)
|
2004-05-25 |
2005-12-01 |
Hofstadler Steven A |
Methods for rapid forensic analysis of mitochondrial DNA
|
|
US7811753B2
(en)
|
2004-07-14 |
2010-10-12 |
Ibis Biosciences, Inc. |
Methods for repairing degraded DNA
|
|
EP1771571A2
(en)
*
|
2004-07-30 |
2007-04-11 |
Targeted Genetics Corporation |
Recombinant aav based vaccine methods
|
|
US7309589B2
(en)
*
|
2004-08-20 |
2007-12-18 |
Vironix Llc |
Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
|
|
WO2006135400A2
(en)
|
2004-08-24 |
2006-12-21 |
Isis Pharmaceuticals, Inc. |
Methods for rapid identification of recombinant organisms
|
|
EP1804781A1
(en)
*
|
2004-10-05 |
2007-07-11 |
Merz Pharma GmbH & Co.KGaA |
Novel cyclic and acyclic propenones for treating cns disorders
|
|
US8084207B2
(en)
|
2005-03-03 |
2011-12-27 |
Ibis Bioscience, Inc. |
Compositions for use in identification of papillomavirus
|
|
US8182992B2
(en)
|
2005-03-03 |
2012-05-22 |
Ibis Biosciences, Inc. |
Compositions for use in identification of adventitious viruses
|
|
US8999678B2
(en)
*
|
2005-04-07 |
2015-04-07 |
The Trustees Of The University Of Pennsylvania |
Method of increasing the function of an AAV vector
|
|
WO2006119432A2
(en)
*
|
2005-04-29 |
2006-11-09 |
The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services |
Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
|
|
EP1904655A2
(en)
|
2005-07-21 |
2008-04-02 |
Isis Pharmaceuticals, Inc. |
Methods for rapid identification and quantitation of nucleic acid variants
|
|
WO2007100397A2
(en)
*
|
2005-11-28 |
2007-09-07 |
Isis Pharmaceuticals, Inc. |
Compositions for use in identification of adventitious contaminant viruses
|
|
US7588772B2
(en)
|
2006-03-30 |
2009-09-15 |
Board Of Trustees Of The Leland Stamford Junior University |
AAV capsid library and AAV capsid proteins
|
|
EP2018421B1
(en)
|
2006-04-28 |
2012-12-19 |
The Trustees of the University of Pennsylvania |
Scalable production method for aav
|
|
EP2044199B1
(en)
*
|
2006-07-25 |
2012-11-14 |
Celladon Corporation |
Extended antegrade epicardial coronary infusion of adeno-associated viral vectors comprising serca2a for gene therapy
|
|
EP2064332B1
(en)
|
2006-09-14 |
2012-07-18 |
Ibis Biosciences, Inc. |
Targeted whole genome amplification method for identification of pathogens
|
|
JP5680304B2
(ja)
|
2007-02-23 |
2015-03-04 |
アイビス バイオサイエンシズ インコーポレイティッド |
迅速な法医学的ｄｎａ分析法
|
|
EP2623605B1
(en)
*
|
2007-04-09 |
2018-11-28 |
University of Florida Research Foundation, Inc. |
RAAV vector compositions having tyrosine-modified capsid proteins and methods for use
|
|
US9611302B2
(en)
|
2007-04-09 |
2017-04-04 |
University Of Florida Research Foundation, Inc. |
High-transduction-efficiency RAAV vectors, compositions, and methods of use
|
|
US9725485B2
(en)
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
|
US9598724B2
(en)
|
2007-06-01 |
2017-03-21 |
Ibis Biosciences, Inc. |
Methods and compositions for multiple displacement amplification of nucleic acids
|
|
EP2058401A1
(en)
*
|
2007-10-05 |
2009-05-13 |
Genethon |
Widespread gene delivery to motor neurons using peripheral injection of AAV vectors
|
|
CN102159713A
(zh)
|
2008-05-20 |
2011-08-17 |
Eos神经科学公司 |
用于递送光敏蛋白的载体和使用方法
|
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
|
WO2010033625A1
(en)
|
2008-09-16 |
2010-03-25 |
Ibis Biosciences, Inc. |
Microplate handling systems and related computer program products and methods
|
|
EP2347254A2
(en)
|
2008-09-16 |
2011-07-27 |
Ibis Biosciences, Inc. |
Sample processing units, systems, and related methods
|
|
WO2010033599A2
(en)
|
2008-09-16 |
2010-03-25 |
Ibis Biosciences, Inc. |
Mixing cartridges, mixing stations, and related kits, systems, and methods
|
|
EP2396803A4
(en)
|
2009-02-12 |
2016-10-26 |
Ibis Biosciences Inc |
IONIZATION PROBE ASSEMBLIES
|
|
ES2724122T3
(es)
|
2009-04-30 |
2019-09-06 |
Univ Pennsylvania |
Composiciones para dirigir células de las vías respiratorias de conducción que comprenden construcciones de virus adenoasociado
|
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
|
WO2010143761A1
(ko)
*
|
2009-06-12 |
2010-12-16 |
(주)바이오니아 |
미지시료 내 감염성 미생물을 신속하게 검출하는 방법
|
|
EP2454000A4
(en)
|
2009-07-17 |
2016-08-10 |
Ibis Biosciences Inc |
SYSTEMS FOR IDENTIFYING BIOLOGICAL SUBSTANCES
|
|
US8950604B2
(en)
|
2009-07-17 |
2015-02-10 |
Ibis Biosciences, Inc. |
Lift and mount apparatus
|
|
US20120244127A1
(en)
|
2009-10-01 |
2012-09-27 |
The Trustees Of The University Of Pennsylvania |
AAV Vectors Expressing SEC10 for Treating Kidney Damage
|
|
US9890408B2
(en)
|
2009-10-15 |
2018-02-13 |
Ibis Biosciences, Inc. |
Multiple displacement amplification
|
|
SG10201908848RA
(en)
|
2010-03-29 |
2019-10-30 |
Univ Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
|
DK2826860T3
(en)
|
2010-04-23 |
2018-12-03 |
Univ Massachusetts |
CNS targeting AAV vectors and methods for their use
|
|
CA2833905C
(en)
|
2010-04-23 |
2019-09-10 |
University Of Massachusetts |
Multicistronic expression constructs
|
|
EP2561075B1
(en)
|
2010-04-23 |
2018-06-27 |
University of Massachusetts |
Aav-based treatment of cholesterol-related disorders
|
|
US9309534B2
(en)
|
2010-07-12 |
2016-04-12 |
Universidad Autonoma De Barcelona |
Gene therapy composition for use in diabetes treatment
|
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
EP2699688A1
(en)
|
2011-04-20 |
2014-02-26 |
The Trustees Of The University Of Pennsylvania |
Regimens and compositions for aav-mediated passive immunization of airborne pathogens
|
|
EP3318634A1
(en)
|
2011-04-21 |
2018-05-09 |
University of Massachusetts |
Raav-based compositions and methods for treating diseases involving dominant-negative or gain of function mutations
|
|
DK4005603T3
(da)
|
2011-04-22 |
2024-11-25 |
Univ California |
Adeno-associerede virus-virioner med variant kapsid og fremgangsmåder til anvendelse heraf
|
|
US9169299B2
(en)
|
2011-08-24 |
2015-10-27 |
The Board Of Trustees Of The Leleand Stanford Junior University |
AAV capsid proteins for nucleic acid transfer
|
|
US20130136729A1
(en)
*
|
2011-11-11 |
2013-05-30 |
University of Virginia Patent Foundation, d/b/a University of Virginia Licensing & Ventures Group |
Compositions and methods for targeting and treating diseases and injuries using adeno-associated virus vectors
|
|
WO2013123503A1
(en)
|
2012-02-17 |
2013-08-22 |
The Children's Hospital Of Philadelphia |
Aav vector compositions and methods for gene transfer to cells, organs and tissues
|
|
US10093947B2
(en)
*
|
2012-02-28 |
2018-10-09 |
Cornell University |
AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
|
|
US10004811B2
(en)
*
|
2012-04-13 |
2018-06-26 |
Cornell University |
Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
|
|
US10294281B2
(en)
|
2012-05-15 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
High-transduction-efficiency rAAV vectors, compositions, and methods of use
|
|
US12358954B2
(en)
|
2012-05-15 |
2025-07-15 |
University Of Florida Research Foundation, Incorporated |
Capsid-modified rAAV vector compositions and methods therefor
|
|
EP2692868A1
(en)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adeno-associated viral (AAV) vectors useful for transducing adipose tissue
|
|
US9567376B2
(en)
|
2013-02-08 |
2017-02-14 |
The Trustees Of The University Of Pennsylvania |
Enhanced AAV-mediated gene transfer for retinal therapies
|
|
DK2956477T4
(da)
|
2013-02-15 |
2024-04-15 |
Bioverativ Therapeutics Inc |
Optimeret faktor viii-gen
|
|
US8957044B2
(en)
|
2013-03-01 |
2015-02-17 |
Wake Forest University Health Sciences |
Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
|
|
SG10201707319UA
(en)
|
2013-03-15 |
2017-10-30 |
Univ Pennsylvania |
Compositions and methods for treating mpsi
|
|
US9719106B2
(en)
|
2013-04-29 |
2017-08-01 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
|
|
CA2907799A1
(en)
|
2013-05-31 |
2014-12-04 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
|
CA3209883A1
(en)
|
2013-07-22 |
2015-01-29 |
The Children's Hospital Of Philadelphia |
Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
|
|
HUE052814T2
(hu)
|
2014-01-31 |
2021-05-28 |
Temple Univ Of The Commonwealth System |
A szívelégtelenség terápiájához célfehérjeként alkamazott BAG3
|
|
GB201403684D0
(en)
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
|
US10072251B2
(en)
|
2014-02-19 |
2018-09-11 |
University Of Massachusetts |
Recombinant AAVS having useful transcytosis properties
|
|
WO2015138357A2
(en)
|
2014-03-09 |
2015-09-17 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of otc deficency
|
|
ES3042252T3
(en)
|
2014-03-17 |
2025-11-19 |
Adverum Biotechnologies Inc |
Compositions and methods for enhanced gene expression in cone cells
|
|
AU2015231294B2
(en)
|
2014-03-18 |
2020-10-29 |
University Of Massachusetts |
rAAV-based compositions and methods for treating amyotrophic lateral sclerosis
|
|
EP3628334B1
(en)
|
2014-03-21 |
2023-06-28 |
Genzyme Corporation |
Gene therapy for retinitis pigmentosa
|
|
EP2933335A1
(en)
|
2014-04-18 |
2015-10-21 |
Genethon |
A method of treating peripheral neuropathies and motor neuron diseases
|
|
WO2015164723A1
(en)
|
2014-04-25 |
2015-10-29 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
|
WO2015164786A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
|
US11555059B2
(en)
|
2014-04-25 |
2023-01-17 |
The Trustees Of The University Of Pennsylvania |
LDLR variants and their use in compositions for reducing cholesterol levels
|
|
DK3142750T3
(da)
|
2014-05-13 |
2020-09-14 |
Univ Pennsylvania |
Sammensætninger omfattende aav, som udtrykker dobbelt-antistofkonstrukter og anvendelser deraf
|
|
WO2015187825A2
(en)
|
2014-06-03 |
2015-12-10 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
|
WO2015191508A1
(en)
|
2014-06-09 |
2015-12-17 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
|
EP2960336A1
(en)
|
2014-06-27 |
2015-12-30 |
Genethon |
Efficient systemic treatment of dystrophic muscle pathologies
|
|
US11008561B2
(en)
|
2014-06-30 |
2021-05-18 |
Bioverativ Therapeutics Inc. |
Optimized factor IX gene
|
|
CN107074805B
(zh)
|
2014-07-03 |
2021-02-26 |
德州大学系统董事会 |
用于治疗疾病的gls1抑制剂
|
|
EP4012035B1
(en)
|
2014-09-16 |
2024-11-06 |
Genzyme Corporation |
Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
|
|
WO2016044478A1
(en)
|
2014-09-16 |
2016-03-24 |
Genzyme Corporation |
Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
|
|
WO2016054554A1
(en)
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
|
EP3795580A1
(en)
|
2014-10-03 |
2021-03-24 |
University of Massachusetts |
High efficiency library-identified aav vectors
|
|
WO2016065001A1
(en)
|
2014-10-21 |
2016-04-28 |
University Of Massachusetts |
Recombinant aav variants and uses thereof
|
|
CN112553229A
(zh)
|
2014-11-05 |
2021-03-26 |
沃雅戈治疗公司 |
用于治疗帕金森病的aadc多核苷酸
|
|
RU2020108189A
(ru)
|
2014-11-14 |
2020-03-11 |
Вояджер Терапьютикс, Инк. |
Композиции и способы лечения бокового амиотрофического склероза (als)
|
|
MX2017006217A
(es)
|
2014-11-14 |
2018-05-02 |
Voyager Therapeutics Inc |
Polinucleotidos moduladores.
|
|
EP3230441A4
(en)
|
2014-12-12 |
2018-10-03 |
Voyager Therapeutics, Inc. |
Compositions and methods for the production of scaav
|
|
EP3242945B1
(en)
|
2015-01-07 |
2021-09-01 |
Universitat Autònoma de Barcelona |
Single-vector gene construct comprising insulin and glucokinase genes
|
|
WO2016115503A1
(en)
|
2015-01-16 |
2016-07-21 |
Voyager Therapeutics, Inc. |
Central nervous system targeting polynucleotides
|
|
IL296391B2
(en)
|
2015-01-20 |
2024-06-01 |
Genzyme Corp |
Analytical ultracentrifugation for characterization of recombinant viral particles
|
|
US20180030096A1
(en)
|
2015-02-03 |
2018-02-01 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
|
JP6929791B2
(ja)
|
2015-02-09 |
2021-09-01 |
デューク ユニバーシティ |
エピゲノム編集のための組成物および方法
|
|
NZ772772A
(en)
|
2015-02-10 |
2024-12-20 |
Genzyme Corp |
Enhanced delivery of viral particles to the striatum and cortex
|
|
SG11201706444TA
(en)
|
2015-02-10 |
2017-09-28 |
Genzyme Corp |
VARIANT RNAi
|
|
US10584321B2
(en)
|
2015-02-13 |
2020-03-10 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
|
CN114480502A
(zh)
|
2015-03-02 |
2022-05-13 |
阿德夫拉姆生物技术股份有限公司 |
用于将多核苷酸玻璃体内递送到视网膜视锥的组合物和方法
|
|
JP2018509164A
(ja)
|
2015-03-10 |
2018-04-05 |
ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク |
組換えＧｌｕｔ１アデノ随伴ウイルスベクターコンストラクトおよびＧｌｕｔ１発現を回復させる方法
|
|
WO2016154344A1
(en)
|
2015-03-24 |
2016-09-29 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
|
EP4491733A3
(en)
|
2015-04-23 |
2025-03-26 |
University of Massachusetts |
Modulation of aav vector transgene expression
|
|
CA3021949C
(en)
|
2015-04-24 |
2023-10-17 |
University Of Massachusetts |
Modified aav constructs and uses thereof
|
|
EP3288594B1
(en)
|
2015-04-27 |
2022-06-29 |
The Trustees of The University of Pennsylvania |
Dual aav vector system for crispr/cas9 mediated correction of human disease
|
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
|
US11535665B2
(en)
|
2015-05-13 |
2022-12-27 |
The Trustees Of The University Of Pennsylvania |
AAV-mediated expression of anti-influenza antibodies and methods of use thereof
|
|
WO2016186772A2
(en)
|
2015-05-16 |
2016-11-24 |
Genzyme Corporation |
Gene editing of deep intronic mutations
|
|
HUE068603T2
(hu)
|
2015-06-23 |
2025-01-28 |
Childrens Hospital Philadelphia |
Módosított IX-es faktor, valamint készítmények, eljárások és alkalmazások sejtekbe, szervekbe és szövetekbe történõ géntranszferhez
|
|
US10676735B2
(en)
|
2015-07-22 |
2020-06-09 |
Duke University |
High-throughput screening of regulatory element function with epigenome editing technologies
|
|
AU2016302335B2
(en)
|
2015-08-06 |
2022-08-04 |
The Trustees Of The University Of Pennsylvania |
GLP-1 and use thereof in compositions for treating metabolic diseases
|
|
CN108351350B
(zh)
|
2015-08-25 |
2022-02-18 |
杜克大学 |
使用rna指导型内切核酸酶改善基因组工程特异性的组合物和方法
|
|
CN108137664B
(zh)
|
2015-08-31 |
2021-11-26 |
宾夕法尼亚州大学信托人 |
用于治疗伴侣动物的aav-epo
|
|
US10988519B2
(en)
|
2015-09-24 |
2021-04-27 |
The Trustees Of The University Of Pennsylvania |
Composition and method for treating complement-mediated disease
|
|
JP7064214B2
(ja)
|
2015-09-28 |
2022-05-10 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
抗体回避性ウイルスベクターのための方法および組成物
|
|
WO2017062750A1
(en)
|
2015-10-09 |
2017-04-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treating stargardt's disease and other ocular disorders
|
|
US11970710B2
(en)
|
2015-10-13 |
2024-04-30 |
Duke University |
Genome engineering with Type I CRISPR systems in eukaryotic cells
|
|
WO2017070525A1
(en)
|
2015-10-22 |
2017-04-27 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance in neurodegenerative disease
|
|
US11426469B2
(en)
|
2015-10-22 |
2022-08-30 |
University Of Massachusetts |
Prostate-targeting adeno-associated virus serotype vectors
|
|
WO2017075335A1
(en)
|
2015-10-28 |
2017-05-04 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
CA3003435A1
(en)
|
2015-10-28 |
2017-05-04 |
The Trustees Of The University Of Pennsylvania |
Intrathecal administration of adeno-associated-viral vectors for gene therapy
|
|
HK1254836A1
(zh)
|
2015-10-30 |
2019-07-26 |
Nbe-Therapeutics Ag |
抗-ror1抗体
|
|
AU2016362477A1
(en)
|
2015-12-02 |
2018-06-14 |
Voyager Therapeutics, Inc. |
Assays for the detection of AAV neutralizing antibodies
|
|
FR3044926B1
(fr)
|
2015-12-09 |
2020-01-31 |
Genethon |
Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
|
|
US11015173B2
(en)
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV1
|
|
WO2017100676A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aav8
|
|
US11098286B2
(en)
|
2015-12-11 |
2021-08-24 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV9
|
|
EP3387118B1
(en)
|
2015-12-11 |
2022-04-06 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for aavrh10
|
|
CA3008142A1
(en)
|
2015-12-11 |
2017-06-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
|
JP7057281B2
(ja)
|
2015-12-14 |
2022-04-19 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
眼疾患のための遺伝子療法
|
|
JP7061067B2
(ja)
|
2015-12-14 |
2022-04-27 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
クリグラー・ナジャー症候群の処置のための組成物
|
|
CA3008268A1
(en)
|
2015-12-15 |
2017-06-22 |
Genzyme Corporation |
Adeno-associated viral vectors for treating mucolipidosis type ii
|
|
BR112018012660B1
(pt)
|
2015-12-22 |
2023-12-19 |
Board Of Regents, The University Of Texas System |
Sal, solvato, ou polimorfo de um composto; polimorfo de composto sólido; composição; e uso de um sal, solvato ou polimorfo
|
|
MX2018008926A
(es)
|
2016-01-20 |
2019-01-10 |
Scripps Research Inst |
Composiciones de anticuerpo contra ror1 y métodos relacionados.
|
|
KR20180118659A
(ko)
|
2016-02-01 |
2018-10-31 |
바이오버라티브 테라퓨틱스 인크. |
최적화된 viii 인자 유전자
|
|
EP3411059A4
(en)
*
|
2016-02-02 |
2019-10-16 |
University Of Massachusetts |
METHOD FOR INCREASING THE EFFECTIVENESS OF THE SYSTEMIC DELIVERY OF AVV GENES TO THE CENTRAL NERVOUS SYSTEM
|
|
WO2017136500A1
(en)
|
2016-02-03 |
2017-08-10 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type i
|
|
EP3413928B1
(en)
|
2016-02-12 |
2022-04-20 |
University of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
|
US10729789B2
(en)
*
|
2016-03-01 |
2020-08-04 |
University Of Virginia Patent Foundation |
Compositions and methods for adeno-associated virus mediated gene expression in myofibroblast-like cells
|
|
US11207426B2
(en)
|
2016-04-05 |
2021-12-28 |
University Of Massachusetts |
Compositions and methods for selective inhibition of grainyhead-like protein expression
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
US20190127713A1
(en)
|
2016-04-13 |
2019-05-02 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
AU2017248656B2
(en)
*
|
2016-04-15 |
2023-07-27 |
The Trustees Of The University Of Pennsylvania |
Novel AAV8 mutant capsids and compositions containing same
|
|
WO2017181113A1
(en)
|
2016-04-15 |
2017-10-19 |
The Trustees Of The University Of Pennsyvania |
Gene therapy for treating mucopolysaccharidosis type ii
|
|
WO2017181105A1
(en)
|
2016-04-15 |
2017-10-19 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
|
WO2017180857A1
(en)
|
2016-04-15 |
2017-10-19 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating hemophilia a
|
|
WO2017180861A1
(en)
|
2016-04-15 |
2017-10-19 |
The Trustees Of The University Of Pennsulvania |
Gene therapy for treating hemophilia b
|
|
IL322403A
(en)
|
2016-04-15 |
2025-09-01 |
Univ Pennsylvania |
Preparations for the treatment of wet age-related macular degeneration
|
|
US11401527B2
(en)
|
2016-04-17 |
2022-08-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for prophylaxis of organophosphates
|
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
GB201608046D0
(en)
*
|
2016-05-09 |
2016-06-22 |
Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The |
Treatment of complement-mediated disorders
|
|
CN116333057A
(zh)
|
2016-05-13 |
2023-06-27 |
4D分子治疗有限公司 |
腺相关病毒变体衣壳和其使用方法
|
|
AU2017267665C1
(en)
|
2016-05-18 |
2023-10-05 |
Voyager Therapeutics, Inc. |
Modulatory polynucleotides
|
|
BR112018073472A2
(pt)
|
2016-05-18 |
2019-08-27 |
Voyager Therapeutics, Inc. |
composições e métodos de tratamento da doença de huntington
|
|
CN109313018B
(zh)
*
|
2016-06-08 |
2021-12-10 |
索尼公司 |
成像控制装置和方法、以及车辆
|
|
WO2017218852A1
(en)
|
2016-06-15 |
2017-12-21 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
|
KR20190096329A
(ko)
|
2016-07-05 |
2019-08-19 |
유니버시티 오브 매사추세츠 |
녹내장에서 신경보호 요법으로서 sfasl의 aav2-매개된 유전자 전달
|
|
KR102526506B1
(ko)
|
2016-07-08 |
2023-05-03 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
Rdh12가 연루된 장애 및 질환의 치료를 위한 방법 및 조성물
|
|
EP4275747A3
(en)
|
2016-07-19 |
2024-01-24 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
|
WO2018022511A1
(en)
|
2016-07-25 |
2018-02-01 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
|
IL263801B2
(en)
|
2016-07-26 |
2024-01-01 |
Biomarin Pharm Inc |
Novel adeno-associated virus capsid proteins
|
|
CA3029833A1
(en)
|
2016-07-29 |
2018-02-01 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
|
US11698377B2
(en)
|
2016-08-15 |
2023-07-11 |
Genzyme Corporation |
Methods for detecting AAV
|
|
AU2017313917B2
(en)
|
2016-08-18 |
2023-12-21 |
The Regents Of The University Of California |
CRISPR-Cas genome engineering via a modular AAV delivery system
|
|
WO2018044933A1
(en)
|
2016-08-30 |
2018-03-08 |
The Regents Of The University Of California |
Methods for biomedical targeting and delivery and devices and systems for practicing the same
|
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
|
EP3518985A4
(en)
|
2016-09-29 |
2020-08-05 |
University of Florida Research Foundation, Incorporated |
AAVRH.10 VARIANTS WITH HOST ANTIBODY EXHAUST CAPACITIES AND MODIFIED TISSUE TARGETING PROPERTIES
|
|
US11578340B2
(en)
|
2016-10-13 |
2023-02-14 |
University Of Massachusetts |
AAV capsid designs
|
|
AU2017345470B2
(en)
|
2016-10-19 |
2023-08-03 |
Adverum Biotechnologies, Inc. |
Modified AAV capsids and uses thereof
|
|
EP3548065B1
(en)
|
2016-12-01 |
2022-11-09 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Pharmaceutical compositions for the treatment of retinal degenerative diseases
|
|
WO2018112225A1
(en)
*
|
2016-12-14 |
2018-06-21 |
The J. David Gladstone Institutes |
Methods and compositions for generating a deletion library and for identifying a defective interfering particle (dip)
|
|
EP3562494A4
(en)
|
2016-12-30 |
2020-08-19 |
The Trustees Of The University Of Pennsylvania |
GENE THERAPY FOR THE TREATMENT OF PHENYLKETONURIS
|
|
KR20190106990A
(ko)
|
2017-01-20 |
2019-09-18 |
유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 |
제대혈 이식(ucbt) 및 증가된 갈락토세레브로시다아제(galc) 발현을 이용한 크라베병의 치료
|
|
KR20250022877A
(ko)
|
2017-01-31 |
2025-02-17 |
리젠엑스바이오 인크. |
완전히-인간 글리코실화된 인간 알파-l-이두로니다아제(idua)를 이용한 뮤코다당증 1형의 치료
|
|
KR20190118163A
(ko)
|
2017-02-20 |
2019-10-17 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
가족성 고콜레스테롤혈증을 치료하기 위한 유전자 요법
|
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
US10786568B2
(en)
|
2017-02-28 |
2020-09-29 |
The Trustees Of The University Of Pennsylvania |
AAV mediated influenza vaccines
|
|
SI3589730T1
(sl)
|
2017-02-28 |
2024-04-30 |
The Trustees Of The University Of Pennsylvania |
Adeno-povezan virus (AAV) clade F vektor in njihova uporaba
|
|
CN119752819A
(zh)
|
2017-03-01 |
2025-04-04 |
宾夕法尼亚州立大学托管会 |
用于眼部病症的基因疗法
|
|
WO2018158397A1
(en)
|
2017-03-02 |
2018-09-07 |
Genethon |
Method for removing anti-aav antibodies from a blood-derived composition
|
|
JP7341900B2
(ja)
|
2017-03-03 |
2023-09-11 |
オブシディアン セラピューティクス， インコーポレイテッド |
免疫療法のためのｃｄ１９組成物及び方法
|
|
AU2018226857B2
(en)
|
2017-03-03 |
2025-01-02 |
Obsidian Therapeutics, Inc. |
Compositions and methods for immunotherapy
|
|
CN118360335A
(zh)
|
2017-04-05 |
2024-07-19 |
马萨诸塞大学 |
小基因治疗
|
|
US11499154B2
(en)
|
2017-04-10 |
2022-11-15 |
Genethon |
Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies
|
|
WO2018191666A1
(en)
|
2017-04-14 |
2018-10-18 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2 sulfatase (ids) produced by human neural or glial cells
|
|
US11879133B2
(en)
|
2017-04-24 |
2024-01-23 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
|
CN111108198A
(zh)
|
2017-05-05 |
2020-05-05 |
沃雅戈治疗公司 |
治疗亨廷顿病的组合物和方法
|
|
CA3061652A1
(en)
|
2017-05-05 |
2018-11-08 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (als)
|
|
EP3622073A4
(en)
|
2017-05-09 |
2021-01-06 |
University of Massachusetts |
METHOD FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
IL316926A
(en)
|
2017-05-11 |
2025-01-01 |
Univ Pennsylvania |
Gene therapy for neuronal ceroid lipofuscinosis
|
|
CA3099990A1
(en)
|
2017-05-12 |
2018-11-15 |
University Of Massachusetts |
Viral vector production
|
|
CN108103058A
(zh)
*
|
2017-05-12 |
2018-06-01 |
北京五加和分子医学研究所有限公司 |
一种i型糖尿病的基因治疗药物
|
|
IL306098A
(en)
|
2017-05-24 |
2023-11-01 |
Univ Barcelona Autonoma |
Viral expression vectors containing the coding sequence for FIBROBLAST GROWTH FACTOR 21 (FGF21)
|
|
CA3098592A1
(en)
|
2017-05-31 |
2018-12-06 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating peroxisomal disorders
|
|
BR112019025732A2
(pt)
|
2017-06-06 |
2020-06-30 |
University Of Massachusetts |
vetores de aav auto-reguladores para expressão segura de mecp2 na síndrome de rett
|
|
WO2018232149A1
(en)
|
2017-06-14 |
2018-12-20 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
|
US10693918B2
(en)
|
2017-06-15 |
2020-06-23 |
Palo Alto Networks, Inc. |
Radio access technology based security in service provider networks
|
|
US10708306B2
(en)
|
2017-06-15 |
2020-07-07 |
Palo Alto Networks, Inc. |
Mobile user identity and/or SIM-based IoT identity and application identity based security enforcement in service provider networks
|
|
US10812532B2
(en)
|
2017-06-15 |
2020-10-20 |
Palo Alto Networks, Inc. |
Security for cellular internet of things in mobile networks
|
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
|
US11050789B2
(en)
|
2017-06-15 |
2021-06-29 |
Palo Alto Networks, Inc. |
Location based security in service provider networks
|
|
US10721272B2
(en)
|
2017-06-15 |
2020-07-21 |
Palo Alto Networks, Inc. |
Mobile equipment identity and/or IOT equipment identity and application identity based security enforcement in service provider networks
|
|
US10834136B2
(en)
|
2017-06-15 |
2020-11-10 |
Palo Alto Networks, Inc. |
Access point name and application identity based security enforcement in service provider networks
|
|
EP4302768A3
(en)
*
|
2017-06-22 |
2024-05-01 |
Board Of Regents, The University Of Texas System |
Methods for producing regulatory immune cells and uses thereof
|
|
BR112019019015A2
(pt)
|
2017-06-30 |
2020-04-14 |
Univ California |
vírions de vírus adeno-associado com capsídeos variantes e seus métodos de uso
|
|
AU2018298133A1
(en)
|
2017-07-06 |
2020-01-23 |
The Trustees Of The University Of Pennsylvania |
AAV9-mediated gene therapy for treating mucopolysaccharidosis type I
|
|
PL3648783T3
(pl)
|
2017-07-07 |
2024-11-18 |
Genethon |
Nowe polinukleotydy kodujące ludzkie białko fkrp
|
|
CN111132626B
(zh)
|
2017-07-17 |
2024-01-30 |
沃雅戈治疗公司 |
轨迹阵列引导系统
|
|
WO2019028306A2
(en)
|
2017-08-03 |
2019-02-07 |
Voyager Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR ADMINISTRATION OF ADENO-ASSOCIATED VIRUSES
|
|
EP3665193A1
(en)
|
2017-08-07 |
2020-06-17 |
NBE Therapeutics AG |
Anthracycline-based antibody drug conjugates having high in vivo tolerability
|
|
EP3676373A4
(en)
*
|
2017-08-28 |
2021-06-09 |
The Regents of The University of California |
Adeno-associated virus capsid variants and methods of use thereof
|
|
BR112020005436B1
(pt)
|
2017-09-20 |
2022-08-02 |
4D Molecular Therapeutics Inc |
Proteína do capsídeo de variante do vírus adenoassociado, virion do aav recombinante (raav) infeccioso, composições, composições farmacêuticas e usos de virion de raav ou de composições farmacêuticas
|
|
JP7397488B2
(ja)
|
2017-09-22 |
2023-12-13 |
ユニバーシティ オブ マサチューセッツ |
Ｓｏｄ１二重発現ベクターおよびその使用
|
|
WO2019060662A1
(en)
|
2017-09-22 |
2019-03-28 |
The Trustees Of The University Of Pennsylvania |
GENE THERAPY FOR THE TREATMENT OF MUCOPOLYSACCHARIDOSE TYPE II
|
|
MY205041A
(en)
|
2017-09-22 |
2024-09-29 |
Genzyme Corp |
Variant rnai
|
|
AU2018338728B2
(en)
|
2017-09-29 |
2025-01-02 |
Centre National De La Recherche Scientifique (Cnrs) |
Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
|
|
WO2019070891A1
(en)
*
|
2017-10-03 |
2019-04-11 |
Prevail Therapeutics, Inc. |
GENE THERAPIES FOR LYSOSOMAL DISORDERS
|
|
US12441998B2
(en)
|
2017-10-12 |
2025-10-14 |
The Trustees Of Columbia University In The City Of New York |
SLC2A1 lncRNA as a biologic and related treatments and methods
|
|
CN111479924B
(zh)
|
2017-10-16 |
2024-06-14 |
沃雅戈治疗公司 |
肌萎缩性侧索硬化症(als)的治疗
|
|
US20200237799A1
(en)
|
2017-10-16 |
2020-07-30 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
|
CN111727201A
(zh)
|
2017-10-18 |
2020-09-29 |
再生生物股份有限公司 |
完全人源翻译后修饰的抗体治疗剂
|
|
CA3079565A1
(en)
|
2017-10-18 |
2019-04-25 |
Regenxbio Inc. |
Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
|
|
US10722487B2
(en)
|
2017-10-18 |
2020-07-28 |
Board Of Regents, The University Of Texas System |
Glutaminase inhibitor therapy
|
|
FI3717636T3
(fi)
|
2017-11-27 |
2023-06-01 |
4D Molecular Therapeutics Inc |
Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä
|
|
CN111989396A
(zh)
|
2017-11-30 |
2020-11-24 |
宾夕法尼亚州大学信托人 |
用于iiib型粘多糖贮积病的基因疗法
|
|
JP7389744B2
(ja)
|
2017-11-30 |
2023-11-30 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ムコ多糖症ｉｉｉａ型のための遺伝子療法
|
|
BR112020012336A2
(pt)
|
2017-12-19 |
2021-03-30 |
Akouos, Inc. |
Administração de anticorpos terapêuticos mediada por aav para o ouvido interno
|
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
|
US20190256867A1
(en)
|
2018-02-01 |
2019-08-22 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring pah gene function and methods of use thereof
|
|
CN112041437A
(zh)
|
2018-02-19 |
2020-12-04 |
同源药物公司 |
用于恢复f8基因功能的腺相关病毒组合物和其使用方法
|
|
US12558434B2
(en)
|
2018-02-20 |
2026-02-24 |
The Trustees Of The University Of Pennsylvania |
Compositions for treatment of wet age-related macular degeneration
|
|
MX2020008932A
(es)
|
2018-02-27 |
2020-10-01 |
Univ Pennsylvania |
Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidacion reducida de la capside y usos de estos.
|
|
WO2019173434A1
(en)
|
2018-03-06 |
2019-09-12 |
Voyager Therapeutics, Inc. |
Insect cell manufactured partial self-complementary aav genomes
|
|
KR20200135433A
(ko)
|
2018-03-23 |
2020-12-02 |
유니버시티 오브 매사추세츠 |
골 장애 치료를 위한 유전자 치료제
|
|
MX2020010464A
(es)
|
2018-04-03 |
2021-01-29 |
|
Vectores de virus que evitan anticuerpos.
|
|
US12091435B2
(en)
|
2018-04-03 |
2024-09-17 |
Ginkgo Bioworks, Inc. |
Antibody-evading virus vectors
|
|
JP7425738B2
(ja)
|
2018-04-03 |
2024-01-31 |
ギンコ バイオワークス インコーポレイテッド |
眼組織を標的とするウイルスベクター
|
|
US12054724B2
(en)
|
2018-04-10 |
2024-08-06 |
President And Fellows Of Harvard College |
AAV vectors encoding clarin-1 or GJB2 and uses thereof
|
|
EP3781677A4
(en)
|
2018-04-16 |
2022-01-19 |
University of Massachusetts |
COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITTING
|
|
US12460226B2
(en)
|
2018-04-16 |
2025-11-04 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating duchenne muscular dystrophy
|
|
CA3096293A1
(en)
|
2018-04-27 |
2019-10-31 |
Rocket Pharmaceuticals, Ltd. |
Gene therapy for cns degeneration
|
|
US11472848B2
(en)
|
2018-04-27 |
2022-10-18 |
University Of Massachusetts |
AAV capsids identified by in vivo library selection
|
|
US20210231560A1
(en)
|
2018-04-29 |
2021-07-29 |
Regenxbio Inc. |
Systems and methods of spectrophotometry for the determination of genome content, capsid content and full/empty ratios of adeno-associated virus particles
|
|
CA3098565A1
(en)
|
2018-04-29 |
2019-11-07 |
Claire G. ZHANG |
Scalable clarification process for recombinant aav production
|
|
US20210207168A1
(en)
|
2018-05-08 |
2021-07-08 |
Rutgers, The State University Of New Jersey |
Aav-compatible laminin-linker polymerization proteins
|
|
JP2021522811A
(ja)
|
2018-05-09 |
2021-09-02 |
ビオマリン プハルマセウトイカル インコーポレイテッド |
フェニルケトン尿症の治療方法
|
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
|
AU2019268330A1
(en)
|
2018-05-15 |
2020-11-26 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of Parkinson's disease
|
|
TW202015742A
(zh)
|
2018-05-15 |
2020-05-01 |
美商航海家醫療公司 |
投遞腺相關病毒（ａａｖ）之組成物和方法
|
|
EP3793686A1
(en)
|
2018-05-16 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Aav serotypes for brain specific payload delivery
|
|
WO2019222444A2
(en)
|
2018-05-16 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Directed evolution
|
|
US12163129B2
(en)
|
2018-06-08 |
2024-12-10 |
University Of Massachusetts |
Antisense oligonucleotides to restore dysferlin protein expression in dysferlinopathy patient cells
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
US12060567B2
(en)
|
2018-06-13 |
2024-08-13 |
Voyager Therapeutics, Inc. |
Engineered untranslated regions (UTR) for AAV production
|
|
KR102930150B1
(ko)
|
2018-06-14 |
2026-02-25 |
리젠엑스바이오 인크. |
재조합 aav 생성을 위한 음이온 교환 크로마토그래피
|
|
US20210254103A1
(en)
|
2018-07-02 |
2021-08-19 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
|
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
|
CN112512596B
(zh)
|
2018-07-12 |
2025-12-12 |
火箭制药有限公司 |
治疗danon病的基因治疗载体
|
|
AU2019304569B2
(en)
|
2018-07-17 |
2023-07-06 |
Helixmith Co., Ltd |
Treatment of neuropathy with DNA constructs expressing IGF-1 isoforms
|
|
MX2021000810A
(es)
|
2018-07-24 |
2021-04-28 |
Voyager Therapeutics Inc |
Sistemas y metodos para producir formulaciones de terapia genetica.
|
|
US12188040B2
(en)
*
|
2018-07-30 |
2025-01-07 |
Gene Therapy Research Institution Co., Ltd. |
Method for enhancing gene expression using AAV vector
|
|
MX2021001395A
(es)
|
2018-08-03 |
2021-08-11 |
Genzyme Corp |
Arni variante contra alfa-sinucleína.
|
|
EP3833745A1
(en)
|
2018-08-10 |
2021-06-16 |
REGENXBIO Inc. |
Scalable method for recombinant aav production
|
|
KR20210102870A
(ko)
|
2018-08-30 |
2021-08-20 |
테나야 테라퓨틱스, 인코포레이티드 |
미오카르딘 및 ascl1을 사용한 심장 세포 재프로그래밍
|
|
CA3113470A1
(en)
|
2018-09-28 |
2020-04-02 |
President And Fellows Of Harvard College |
Mutant reverse tetracycline transactivators for expression of genes
|
|
CN113453702A
(zh)
|
2018-09-28 |
2021-09-28 |
哈佛大学的校长及成员们 |
细胞重编程以逆转衰老并促进组织和组织再生
|
|
EP3856762A1
(en)
|
2018-09-28 |
2021-08-04 |
Voyager Therapeutics, Inc. |
Frataxin expression constructs having engineered promoters and methods of use thereof
|
|
US12274733B2
(en)
|
2018-09-28 |
2025-04-15 |
President And Fellows Of Harvard College |
Cellular reprogramming to reverse aging and promote organ and tissue regeneration
|
|
JP7534290B2
(ja)
|
2018-10-01 |
2024-08-14 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Ｇｍ１ガングリオシドーシスの治療に有用な組成物
|
|
JP2022513318A
(ja)
|
2018-10-01 |
2022-02-07 |
ウルトラジェニックス ファーマシューティカル インコーポレイテッド |
プロピオン酸血症を処置するための遺伝子治療
|
|
TW202035689A
(zh)
|
2018-10-04 |
2020-10-01 |
美商航海家醫療公司 |
測量病毒載體粒子的效價及強度之方法
|
|
WO2020072844A1
(en)
|
2018-10-05 |
2020-04-09 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
|
EP4461814A3
(en)
|
2018-10-12 |
2025-02-26 |
Genzyme Corporation |
Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy
|
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
CN112912518A
(zh)
|
2018-10-15 |
2021-06-04 |
再生生物股份有限公司 |
用于测量复制缺陷型病毒载体和病毒的感染性的方法
|
|
CN113166781A
(zh)
|
2018-10-15 |
2021-07-23 |
沃雅戈治疗公司 |
在杆状病毒/Sf9系统中大规模生产rAAV的表达载体
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
CA3116334A1
(en)
|
2018-10-22 |
2020-04-30 |
University Of Rochester |
Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas9 fusion protein
|
|
EP3870600A1
(en)
|
2018-10-24 |
2021-09-01 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
|
EP3880255A1
(en)
|
2018-11-16 |
2021-09-22 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting utrophin gene
|
|
WO2020102645A1
(en)
*
|
2018-11-16 |
2020-05-22 |
Asklepios Biopharmaceutical, Inc. |
Therapeutic adeno-associated virus for treating pompe disease
|
|
EP3887522A1
(en)
|
2018-11-29 |
2021-10-06 |
University of Massachusetts |
Modulation of sptlc1 via recombinant adeno-associated vectors
|
|
WO2020140007A1
(en)
|
2018-12-28 |
2020-07-02 |
University Of Rochester |
Gene therapy for best1 dominant mutations
|
|
PL3906066T3
(pl)
|
2019-01-04 |
2024-09-02 |
Ultragenyx Pharmaceutical Inc. |
Konstrukty do terapii genowej do leczenia choroby wilsona
|
|
BR112021013715A2
(pt)
|
2019-01-14 |
2021-09-21 |
University Of Rochester |
Proteína de fusão, molécula de ácido nucleico, métodos para modular a clivagem, a poliadenilação, ou ambas, de um transcrito de rna, para visualizar rna nuclear e para diminuir o número de rna nuclear ou para clivar rna nuclear, e, uso da proteína de fusão
|
|
EP3911410A1
(en)
|
2019-01-18 |
2021-11-24 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
|
KR20210130158A
(ko)
|
2019-01-31 |
2021-10-29 |
오레곤 헬스 앤드 사이언스 유니버시티 |
Aav 캡시드의 전사 의존적 유도 진화를 사용하는 방법
|
|
US20220054655A1
(en)
|
2019-02-22 |
2022-02-24 |
University Of Massachusetts |
Oxr1 gene therapy
|
|
BR112021015817A2
(pt)
|
2019-02-22 |
2021-10-13 |
The Trustees Of The University Of Pennsylvania |
Vírus adeno-associado recombinante para tratamento de neurodegeneração com início na idade adulta associado a grn
|
|
BR112021016501A2
(pt)
|
2019-02-25 |
2021-10-26 |
Novartis Ag |
Composições e métodos para tratar distrofia cristalina de bietti
|
|
CN113710693B
(zh)
|
2019-02-25 |
2025-07-15 |
马萨诸塞大学 |
Dna结合结构域反式激活因子及其用途
|
|
US20220154211A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
|
TW202045728A
(zh)
|
2019-02-26 |
2020-12-16 |
賓州大學委員會 |
用於治療克拉培氏病之組成物
|
|
WO2020176747A1
(en)
|
2019-02-28 |
2020-09-03 |
Regeneron Pharmaceuticals, Inc. |
Adeno-associated virus vectors for the delivery of therapeutics
|
|
JP7637060B2
(ja)
|
2019-03-04 |
2025-02-27 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Ａｋｔ経路を標的とする神経保護遺伝子療法
|
|
JP7698583B2
(ja)
|
2019-03-21 |
2025-06-25 |
ギンコ バイオワークス インコーポレイテッド |
組換えアデノ随伴ウイルスベクター
|
|
JP7635139B2
(ja)
|
2019-03-25 |
2025-02-25 |
ジェネトン |
オーバーラップａａｖベクターを使用する大きいサイズのクアシジストロフィンの産生
|
|
SG11202110607WA
(en)
|
2019-04-01 |
2021-10-28 |
Tenaya Therapeutics Inc |
Adeno-associated virus with engineered capsid
|
|
EP3946467A1
(en)
|
2019-04-03 |
2022-02-09 |
REGENXBIO Inc. |
Gene therapy for eye pathologies
|
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
|
DK3953483T3
(da)
|
2019-04-11 |
2023-12-18 |
Regenxbio Inc |
Fremgangsmåder til størrelseskromatografi til karakterisering af sammensætninger af rekombinant adeno-associeret virus
|
|
US12553036B2
(en)
|
2019-04-12 |
2026-02-17 |
University Of Massachusetts |
GM3 synthase vectors and uses thereof
|
|
AU2020258483A1
(en)
|
2019-04-17 |
2021-11-11 |
Evox Therapeutics, Ltd. |
Compositions of exosomes and AAV
|
|
JP7630443B2
(ja)
|
2019-04-19 |
2025-02-17 |
レジェンクスバイオ インコーポレーテッド |
アデノ随伴ウイルスベクター製剤及び方法
|
|
CA3137135A1
(en)
|
2019-04-19 |
2020-10-22 |
University Of Massachusetts |
Gene therapies for stargardt disease (abca4)
|
|
WO2020219868A1
(en)
|
2019-04-24 |
2020-10-29 |
Regenxbio Inc. |
Fully-human post-translationally modified antibody therapeutics
|
|
WO2020219990A1
(en)
|
2019-04-26 |
2020-10-29 |
President And Fellows Of Harvard College |
Aav vectors encoding mini-pcdh15 and uses thereof
|
|
US20220243225A1
(en)
|
2019-04-29 |
2022-08-04 |
Voyager Therapeutics, Inc. |
SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
|
|
US12516351B2
(en)
*
|
2019-04-29 |
2026-01-06 |
The Trustees Of The University Of Pennsylvania |
AAV capsids and compositions containing same
|
|
AU2020270421A1
(en)
|
2019-05-03 |
2021-11-18 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of metachromatic leukodystrophy
|
|
EP3966227A1
(en)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
WO2020236815A1
(en)
|
2019-05-20 |
2020-11-26 |
University Of Massachusetts |
Minigene therapy
|
|
PH12021552887A1
(en)
*
|
2019-05-24 |
2022-09-05 |
Regeneron Pharma |
Modified viral particles and uses thereof
|
|
PH12021552592A1
(en)
|
2019-05-28 |
2022-06-20 |
Modalis Therapeutics Corp |
Method for treating muscular dystrophy by targeting dmpk gene
|
|
EP3987024A4
(en)
|
2019-06-20 |
2023-11-01 |
University Of Massachusetts |
COMPOSITIONS AND METHODS FOR ENHANCED GENOMIC EDITING
|
|
EP3994253A1
(en)
|
2019-07-02 |
2022-05-11 |
M6P Therapeutics (Switzerland) LLC |
Vector compositions and methods of using same for treatment of lysosomal storage disorders
|
|
CA3137622A1
(en)
|
2019-07-10 |
2021-01-14 |
Masonic Medical Research Institute |
Vgll4 with ucp-1 cis-regulatory element and method of use thereof
|
|
US20220251567A1
(en)
|
2019-07-10 |
2022-08-11 |
Inserm (Institut National De La Santè Et De La Recherche Médicale) |
Methods for the treatment of epilepsy
|
|
JP7654626B2
(ja)
|
2019-07-11 |
2025-04-01 |
サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック |
化学修飾型アデノ随伴ウイルス
|
|
EP3997226A1
(en)
|
2019-07-11 |
2022-05-18 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
|
US10653731B1
(en)
*
|
2019-07-15 |
2020-05-19 |
Vigene Biosciences Inc. |
Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
|
|
US10557149B1
(en)
*
|
2019-07-15 |
2020-02-11 |
Vigene Biosciences, Inc. |
Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
|
|
JP2022544015A
(ja)
|
2019-07-23 |
2022-10-17 |
ユニバーシティ オブ ロチェスター |
ＣＲＩＳＰＲ－Ｃａｓでの標的化されたＲＮＡ切断
|
|
US20220396806A1
(en)
|
2019-07-26 |
2022-12-15 |
Akouos, Inc. |
Methods of treating hearing loss using a secreted target protein
|
|
US20230042103A1
(en)
|
2019-07-26 |
2023-02-09 |
Regenxbio Inc. |
Engineered nucleic acid regulatory element and methods of uses thereof
|
|
WO2021030125A1
(en)
|
2019-08-09 |
2021-02-18 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
WO2021030764A1
(en)
*
|
2019-08-14 |
2021-02-18 |
University Of Florida Research Foundation, Incorporated |
Aav capsid variants for gene therapy
|
|
EP4022070A1
(en)
|
2019-08-26 |
2022-07-06 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
CN114502197A
(zh)
|
2019-08-26 |
2022-05-13 |
再生生物股份有限公司 |
用全人经翻译后修饰的抗VEGF Fab治疗糖尿病性视网膜病变
|
|
KR20220070443A
(ko)
|
2019-08-27 |
2022-05-31 |
버텍스 파마슈티칼스 인코포레이티드 |
반복성 dna와 연관된 장애의 치료용 조성물 및 방법
|
|
US20220333133A1
(en)
|
2019-09-03 |
2022-10-20 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
|
AU2020346062A1
(en)
|
2019-09-13 |
2022-03-24 |
Rutgers, The State University Of New Jersey |
AAV-compatible laminin-linker polymerization proteins
|
|
JP7651562B2
(ja)
|
2019-09-19 |
2025-03-26 |
ジェネトン |
Ｆｋｒｐの心毒性を軽減する遺伝子治療発現系
|
|
WO2021062092A1
(en)
|
2019-09-26 |
2021-04-01 |
Massachusetts Institute Of Technology |
Trans-activated functional rna by strand displacement and uses thereof
|
|
WO2021062096A1
(en)
|
2019-09-26 |
2021-04-01 |
Massachusetts Institute Of Technology |
Microrna-based logic gates and uses thereof
|
|
TW202126284A
(zh)
|
2019-09-30 |
2021-07-16 |
美商百歐維拉提夫治療公司 |
慢病毒載體配製物
|
|
WO2021067598A1
(en)
|
2019-10-04 |
2021-04-08 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
|
US20240108669A1
(en)
|
2019-10-07 |
2024-04-04 |
Regenxbio Inc. |
Adeno-associated virus vector pharmaceutical composition and methods
|
|
US20230121437A1
(en)
|
2019-10-15 |
2023-04-20 |
University Of Massachusetts |
Rna editor-enhanced rna trans-splicing
|
|
EP4045664A1
(en)
*
|
2019-10-16 |
2022-08-24 |
Wuxi Apptec (Shanghai) Co., Ltd. |
A novel aav variant
|
|
IL292297A
(en)
|
2019-10-17 |
2022-06-01 |
Stridebio Inc |
Adeno-associated viral vectors for treatment of niemann-pick disease type c
|
|
CA3161154A1
(en)
|
2019-11-14 |
2021-05-20 |
Biomarin Pharmaceutical Inc. |
Treatment of hereditary angioedema with liver-specific gene therapy vectors
|
|
US20230016983A1
(en)
|
2019-11-19 |
2023-01-19 |
lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) |
Antisense oligonucleotides and thier use for the treatment of cancer
|
|
EP4065596A2
(en)
*
|
2019-11-28 |
2022-10-05 |
RegenxBio Inc. |
Microdystrophin gene therapy constructs and uses thereof
|
|
IL293684A
(en)
|
2019-12-10 |
2022-08-01 |
Takeda Pharmaceuticals Co |
Adeno associated virus vectors for the treatment of hunter disease
|
|
KR20220128632A
(ko)
|
2019-12-31 |
2022-09-21 |
스완바이오 테라퓨틱스 리미티드 |
개선된 aav-abcd1 구축물 및 부신백질이영양증 (ald) 및/또는 부신척수신경병증 (amn)의 치료 또는 예방을 위한 용도
|
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
|
BR112022014563A2
(pt)
|
2020-01-22 |
2022-09-13 |
Regenxbio Inc |
Método para tratamento de um sujeito humano diagnosticado com mucopolissacaridose i (mps i)
|
|
EP4096631A1
(en)
|
2020-01-29 |
2022-12-07 |
RegenxBio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) produced by human neural or glial cells
|
|
EP4097238A1
(en)
|
2020-01-29 |
2022-12-07 |
REGENXBIO Inc. |
Treatment of mucopolysaccharidosis iva
|
|
JP2023512071A
(ja)
|
2020-01-30 |
2023-03-23 |
ウモジャ バイオファーマ， インコーポレイテッド |
二特異性形質導入エンハンサー
|
|
CA3165057A1
(en)
|
2020-02-02 |
2021-08-05 |
James M. Wilson |
Compositions useful for treating gm1 gangliosidosis
|
|
US20230073250A1
(en)
|
2020-02-07 |
2023-03-09 |
University Of Rochester |
Ribozyme-mediated RNA Assembly and Expression
|
|
US20230078498A1
(en)
|
2020-02-07 |
2023-03-16 |
University Of Rochester |
Targeted Translation of RNA with CRISPR-Cas13 to Enhance Protein Synthesis
|
|
EP4103724A1
(en)
|
2020-02-14 |
2022-12-21 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating cdkl5 deficiency disorder
|
|
US20230089312A1
(en)
|
2020-02-25 |
2023-03-23 |
University Of Massachusetts |
Inducible single aav system and uses thereof
|
|
TW202142554A
(zh)
*
|
2020-02-25 |
2021-11-16 |
澳洲兒童醫學研究所 |
腺相關病毒蛋白殼多肽及載體
|
|
CN115552022A
(zh)
|
2020-03-02 |
2022-12-30 |
特纳亚治疗股份有限公司 |
由心肌细胞表达的微rna控制的基因载体
|
|
US20240218367A1
(en)
|
2020-03-27 |
2024-07-04 |
University Of Rochester |
Targeted Destruction of Viral RNA by CRISPR-Cas13
|
|
WO2021195525A1
(en)
|
2020-03-27 |
2021-09-30 |
University Of Rochester |
Crispr-cas13 crrna arrays
|
|
CA3175034A1
(en)
|
2020-03-27 |
2021-09-30 |
UCB Biopharma SRL |
Autonomous knob domain peptides
|
|
TW202204377A
(zh)
|
2020-03-31 |
2022-02-01 |
麻州大學 |
蛋白殼變體及其用途
|
|
WO2021202532A1
(en)
|
2020-03-31 |
2021-10-07 |
Ultragenyx Pharmaceutical Inc. |
Gene therapy for treating propionic acidemia
|
|
AR122409A1
(es)
|
2020-04-03 |
2022-09-07 |
Biomarin Pharm Inc |
Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas
|
|
US20230226223A1
(en)
|
2020-04-10 |
2023-07-20 |
Sola Biosciences Llc |
Compositions and Methods for the Treatment of Protein Aggregation Disorders
|
|
EP4135841A1
(en)
|
2020-04-15 |
2023-02-22 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
BR112022021134A2
(pt)
|
2020-04-20 |
2023-02-14 |
Tenaya Therapeutics Inc |
Vírus adeno-associado com capsídeo projetado
|
|
AU2021265088A1
(en)
|
2020-04-28 |
2022-11-03 |
Sola Biosciences Llc |
Compositions and methods for the treatment of TDP-43 proteinopathies
|
|
BR112022021786A2
(pt)
|
2020-05-12 |
2023-01-17 |
Univ Pennsylvania |
Composições úteis em tratamento de doença de krabbe
|
|
EP4162059A1
(en)
|
2020-05-12 |
2023-04-12 |
The Trustees of The University of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
TW202208406A
(zh)
|
2020-05-13 |
2022-03-01 |
美商阿科奧斯公司 |
用於治療ｋｃｎｑ４相關性聽力損失之組成物及方法
|
|
IL298128A
(en)
|
2020-05-13 |
2023-01-01 |
Akouos Inc |
Compositions and methods for treating slc26a4-associated hearing loss
|
|
WO2021230385A1
(en)
|
2020-05-15 |
2021-11-18 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting utrophin gene
|
|
TW202208632A
(zh)
|
2020-05-27 |
2022-03-01 |
美商同源醫藥公司 |
用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
CA3183251A1
(en)
|
2020-06-05 |
2021-12-09 |
Sola Biosciences Llc |
Compositions and methods for the treatment of synucleinopathies
|
|
IL299167A
(en)
|
2020-06-17 |
2023-02-01 |
Univ Pennsylvania |
Compositions and methods for treating patients with gene therapy
|
|
WO2021255245A2
(en)
|
2020-06-19 |
2021-12-23 |
Genethon |
Gene therapy expression system allowing an adequate expression in the muscles and in the heart of sgcg
|
|
WO2021262963A1
(en)
|
2020-06-24 |
2021-12-30 |
Bioverativ Therapeutics Inc. |
Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein
|
|
CN116194587A
(zh)
|
2020-07-10 |
2023-05-30 |
吉尼松公司 |
一种新的肌肉特异性启动子
|
|
WO2022011262A1
(en)
|
2020-07-10 |
2022-01-13 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating epilepsy
|
|
BR112023000578A2
(pt)
|
2020-07-13 |
2023-05-09 |
Univ Pennsylvania |
Composições úteis para tratamento de doença de charcot-marie-tooth
|
|
EP4182455A1
(en)
|
2020-07-15 |
2023-05-24 |
University of Rochester |
Targeted rna cleavage with dcasl3-rnase fusion proteins
|
|
WO2022017630A1
(en)
|
2020-07-23 |
2022-01-27 |
Ucl Business Ltd |
GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF
|
|
WO2022026409A1
(en)
|
2020-07-27 |
2022-02-03 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
|
WO2022032153A1
(en)
|
2020-08-06 |
2022-02-10 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
|
KR20230042754A
(ko)
|
2020-08-07 |
2023-03-29 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
소포 표적화 단백질 및 이의 용도
|
|
CA3185267A1
(en)
|
2020-08-07 |
2022-02-10 |
Spacecraft Seven, Llc |
Plakophilin-2 (pkp2) gene therapy using aav vector
|
|
CN114075610B
(zh)
*
|
2020-08-11 |
2023-11-17 |
北京荷塘生华医疗科技有限公司 |
检测野生型腺相关病毒的通用引物及其应用
|
|
CA3188956A1
(en)
|
2020-08-14 |
2022-02-17 |
James M. Wilson |
Novel aav capsids and compositions containing same
|
|
CA3189878A1
(en)
|
2020-08-19 |
2022-02-24 |
Colin O'BANION |
Adeno-associated virus vectors for treatment of rett syndrome
|
|
GB202013194D0
(en)
|
2020-08-24 |
2020-10-07 |
Combigene Ab |
Gene therapy for lipodystrophy
|
|
EP4200429A1
(en)
|
2020-08-24 |
2023-06-28 |
The Trustees of The University of Pennsylvania |
Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
|
|
IL300622A
(en)
|
2020-08-26 |
2023-04-01 |
Univ Pennsylvania |
Recombinant adeno-associated virus for the treatment of adult-onset GRN-related neurodegeneration
|
|
WO2022056000A1
(en)
|
2020-09-09 |
2022-03-17 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of duchenne muscular dystrophy
|
|
JP2023540960A
(ja)
|
2020-09-10 |
2023-09-27 |
ルートビヒ－マキシミリアンズ－ウニベルジテート ミュンヘン |
操作されたａａｖベクター
|
|
US12129287B2
(en)
|
2020-09-14 |
2024-10-29 |
President And Fellows Of Harvard College |
Recombinant adeno associated virus encoding clarin-1 and uses thereof
|
|
WO2022060915A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized lanadelumab and administration thereof
|
|
EP4214242A1
(en)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vectorized antibodies for anti-viral therapy
|
|
US20230383278A1
(en)
|
2020-09-18 |
2023-11-30 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
|
US11401531B2
(en)
|
2020-09-24 |
2022-08-02 |
University Of Massachusetts |
AAV vectors encoding NF1 and uses thereof
|
|
JP2023544165A
(ja)
|
2020-10-01 |
2023-10-20 |
ジェンザイム・コーポレーション |
肝臓に向けられた遺伝子補充療法によってｐｋｕを処置するためのヒトｐａｈ発現カセット
|
|
US20240024508A1
(en)
|
2020-10-07 |
2024-01-25 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as high viscosity formulations
|
|
WO2022076591A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as formulations with aggregate formation
|
|
MX2023003699A
(es)
|
2020-10-07 |
2023-04-21 |
Regenxbio Inc |
Virus adenoasociados para el suministro ocular de genoterapia.
|
|
IL301947A
(en)
|
2020-10-07 |
2023-06-01 |
Regenxbio Inc |
Formulations for suprachoroidal administration such as gel formulations
|
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
|
KR20230083287A
(ko)
|
2020-10-07 |
2023-06-09 |
리젠엑스바이오 인크. |
Cln2 질환의 안구 징후에 대한 유전자 요법
|
|
AU2021356684A1
(en)
|
2020-10-09 |
2023-05-11 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
|
CN115698304A
(zh)
|
2020-10-09 |
2023-02-03 |
特纳亚治疗股份有限公司 |
亲斑蛋白-2基因疗法的方法和组合物
|
|
US20230383313A1
(en)
|
2020-10-18 |
2023-11-30 |
The Trustees Of The University Of Pennsylvania |
Improved adeno-associated virus (aav) vector and uses therefor
|
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
|
TW202233841A
(zh)
|
2020-10-28 |
2022-09-01 |
美商銳進科斯生物股份有限公司 |
用於眼適應症之載體化抗ＴＮＦ－α抗體
|
|
WO2022094078A1
(en)
|
2020-10-28 |
2022-05-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of rett syndrome
|
|
CN116457373A
(zh)
|
2020-10-29 |
2023-07-18 |
再生生物股份有限公司 |
用于眼部适应症的载体化TNF-α拮抗剂
|
|
EP4236974A2
(en)
|
2020-10-29 |
2023-09-06 |
RegenxBio Inc. |
Vectorized factor xii antibodies and administration thereof
|
|
WO2022098933A1
(en)
|
2020-11-06 |
2022-05-12 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of dm1 with slucas9 and sacas9
|
|
CN112322791B
(zh)
*
|
2020-11-27 |
2023-10-27 |
福建省农业科学院畜牧兽医研究所 |
一种新型鸭依赖属病毒环介导等温扩增检测引物组及试剂盒
|
|
EP4256065A2
(en)
|
2020-12-01 |
2023-10-11 |
The Trustees of The University of Pennsylvania |
Novel compositions with tissue-specific targeting motifs and compositions containing same
|
|
AU2021391433A1
(en)
|
2020-12-01 |
2023-06-22 |
Akouos, Inc. |
Anti-vegf antibody constructs and related methods for treating vestibular schwannoma associated symptoms
|
|
KR20230128001A
(ko)
|
2020-12-01 |
2023-09-01 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
엔젤만 증후군의 치료를 위한 조성물 및 이의 용도
|
|
KR20230120128A
(ko)
|
2020-12-16 |
2023-08-16 |
리젠엑스바이오 인크. |
재조합 바이러스 입자의 생산 방법
|
|
JP2024500786A
(ja)
|
2020-12-29 |
2024-01-10 |
アコーオス インコーポレイテッド |
Ｃｌｒｎ１関連難聴及び／または視力低下を治療するための組成物及び方法
|
|
TW202241943A
(zh)
|
2020-12-29 |
2022-11-01 |
美商銳進科斯生物股份有限公司 |
Tau特異性抗體基因療法組合物、方法及其用途
|
|
CN116981697A
(zh)
|
2021-01-14 |
2023-10-31 |
森迪生物科学公司 |
可分泌有效载荷调节
|
|
CA3205209A1
(en)
|
2021-01-21 |
2022-07-28 |
Regenxbio Inc. |
Improved production of recombinant polypeptides and viruses
|
|
WO2022159722A1
(en)
|
2021-01-22 |
2022-07-28 |
University Of Massachusetts |
Use of novel mirna-binding site cassettes for antigen-presenting cell detargeting of transgene expression by raav gene therapy vectors
|
|
US20240141375A1
(en)
|
2021-01-27 |
2024-05-02 |
Umoja Biopharma, Inc. |
Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor
|
|
EP4284335A1
(en)
|
2021-02-01 |
2023-12-06 |
RegenxBio Inc. |
Gene therapy for neuronal ceroid lipofuscinoses
|
|
WO2022173605A2
(en)
|
2021-02-10 |
2022-08-18 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
|
|
GB202101958D0
(en)
|
2021-02-12 |
2021-03-31 |
Ucl Business Ltd |
Gene therapy for dopamine transporter deficiency syndrome
|
|
AR124981A1
(es)
|
2021-02-26 |
2023-05-24 |
Takeda Pharmaceuticals Co |
Composición y métodos para el tratamiento de la enfermedad de fabry
|
|
WO2022182959A1
(en)
|
2021-02-26 |
2022-09-01 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/slucas9
|
|
TW202302848A
(zh)
|
2021-02-26 |
2023-01-16 |
美商維泰克斯製藥公司 |
以crispr/sacas9治療第1型肌強直性營養不良之組合物及方法
|
|
EP4301768A2
(en)
|
2021-03-03 |
2024-01-10 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
US20240141378A1
(en)
|
2021-03-03 |
2024-05-02 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
US20240159718A1
(en)
|
2021-03-22 |
2024-05-16 |
Genzyme Corporation |
Size exclusion chromatography analysis of empty and full aav capsids
|
|
WO2022204476A1
(en)
|
2021-03-26 |
2022-09-29 |
The Board Of Regents Of The University Of Texas System |
Nucleotide editing to reframe dmd transcripts by base editing and prime editing
|
|
MX2023012052A
(es)
|
2021-04-12 |
2024-03-15 |
Univ Pennsylvania |
Composiciones útiles para tratar la atrofia muscular espinal y bulbar (sbma).
|
|
EP4334334A1
(en)
|
2021-04-23 |
2024-03-13 |
The Trustees of The University of Pennsylvania |
Novel compositions with brain-specific targeting motifs and compositions containing same
|
|
AU2022261125A1
(en)
|
2021-04-23 |
2023-11-23 |
University Of Rochester |
Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas fusion protein and methods of treatment
|
|
EP4330409A4
(en)
|
2021-04-26 |
2025-04-09 |
University of Massachusetts |
GENE THERAPIES FOR STARGARDT'S DISEASE (ABCA4)
|
|
WO2022229851A1
(en)
|
2021-04-26 |
2022-11-03 |
Crispr Therapeutics Ag |
Compositions and methods for using slucas9 scaffold sequences
|
|
EP4329821A1
(en)
|
2021-04-26 |
2024-03-06 |
RegenxBio Inc. |
Microdystrophin gene therapy administration for treatment of dystrophinopathies
|
|
US20240218397A1
(en)
|
2021-05-04 |
2024-07-04 |
Regenxbio Inc. |
Novel aav vectors and methods and uses thereof
|
|
WO2022234519A1
(en)
|
2021-05-05 |
2022-11-10 |
Crispr Therapeutics Ag |
Compositions and methods for using sacas9 scaffold sequences
|
|
US20240358857A1
(en)
|
2021-05-11 |
2024-10-31 |
Regenxbio Inc. |
Treatment of duchenne muscular dystrophy and combinations thereof
|
|
WO2022272296A2
(en)
|
2021-06-25 |
2022-12-29 |
Homology Medicines, Inc. |
Adeno-associated virus packaging systems
|
|
EP4363437A1
(en)
|
2021-07-01 |
2024-05-08 |
Amicus Therapeutics, Inc. |
Neurotensin variants and tagged proteins comprising neurotensin or sortilin propeptide
|
|
US20240316102A1
(en)
|
2021-07-01 |
2024-09-26 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
|
JP2024523707A
(ja)
|
2021-07-08 |
2024-06-28 |
テナヤ セラピューティクス， インコーポレイテッド |
遺伝子治療のための最適化された発現カセット
|
|
WO2023004331A1
(en)
|
2021-07-19 |
2023-01-26 |
New York University |
Auf1 combination therapies for treatment of muscle degenerative disease
|
|
AU2022318664A1
(en)
|
2021-07-30 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
WO2023010133A2
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
WO2023018637A1
(en)
|
2021-08-09 |
2023-02-16 |
Vertex Pharmaceuticals Incorporated |
Gene editing of regulatory elements
|
|
WO2023019226A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
|
AU2022325955A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
|
KR20240073006A
(ko)
|
2021-08-11 |
2024-05-24 |
사나 바이오테크놀로지, 인크. |
동종이계 세포 요법을 위한 유전자 변형된 1차 세포
|
|
AU2022325231A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
|
EP4396237A4
(en)
|
2021-08-31 |
2025-11-19 |
Scout Bio Inc |
Antigen-binding molecules and their uses
|
|
WO2023039444A2
(en)
|
2021-09-08 |
2023-03-16 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exon 51 for treatment of duchenne muscular dystrophy
|
|
AU2022356427A1
(en)
|
2021-09-30 |
2024-05-09 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
|
TW202332472A
(zh)
|
2021-10-01 |
2023-08-16 |
美商拜奧馬林製藥公司 |
利用ａａｖ基因療法載體進行之遺傳性血管水腫治療及治療性調配物
|
|
US20240384298A1
(en)
|
2021-10-02 |
2024-11-21 |
The Trustees Of The University Of Pennsylvania |
Novel aav capsids and compositions containing same
|
|
WO2023060113A1
(en)
|
2021-10-05 |
2023-04-13 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
CN118202060A
(zh)
|
2021-10-05 |
2024-06-14 |
再生生物股份有限公司 |
用于重组aav生产的组合物和方法
|
|
WO2023060272A2
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
US20250001006A1
(en)
|
2021-10-07 |
2025-01-02 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
|
US20250042958A1
(en)
|
2021-10-08 |
2025-02-06 |
Sola Biosciences Llc |
Compositions and methods for the treatment of proteopathies
|
|
EP4413023A1
(en)
|
2021-10-08 |
2024-08-14 |
SOLA Biosciences LLC |
Compositions and methods for the treatment of p53-mediated cancers
|
|
IL311786A
(en)
|
2021-10-21 |
2024-05-01 |
Vertex Pharma |
hypoimmune cells
|
|
WO2023077092A1
(en)
|
2021-10-28 |
2023-05-04 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
|
US20250295807A1
(en)
|
2021-11-15 |
2025-09-25 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
|
EP4437113A1
(en)
|
2021-11-23 |
2024-10-02 |
University of Massachusetts |
Gene therapy for spinal muscular atrophy
|
|
WO2023102442A1
(en)
|
2021-11-30 |
2023-06-08 |
Jaguar Gene Therapy, Llc |
Gene therapy methods for treatment of diabetes
|
|
WO2023102517A1
(en)
|
2021-12-02 |
2023-06-08 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
|
MX2024007301A
(es)
|
2021-12-17 |
2024-06-26 |
Tafalgie Therapeutics |
Peptidos y metodos para usar en el tratamiento del dolor.
|
|
AU2022423978A1
(en)
|
2021-12-28 |
2024-07-18 |
Chengdu Origen Biotechnology Co., Ltd. |
Modified aav capsid protein and use thereof
|
|
WO2023133593A2
(en)
*
|
2022-01-10 |
2023-07-13 |
University Of Florida Research Foundation, Incorporated |
Aav5 capsid variants
|
|
US20250177495A1
(en)
|
2022-01-10 |
2025-06-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of metachromatic leukodystrophy
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
AR128239A1
(es)
|
2022-01-10 |
2024-04-10 |
Univ Pennsylvania |
Composiciones y métodos útiles para el tratamiento de trastornos mediados por c9orf72
|
|
EP4215614A1
(en)
|
2022-01-24 |
2023-07-26 |
Dynacure |
Combination therapy for dystrophin-related diseases
|
|
KR20240137067A
(ko)
|
2022-01-25 |
2024-09-19 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
개선된 심장 형질도입 및 간의 탈표적화를 위한 aav 캡시드
|
|
EP4473097A1
(en)
|
2022-02-02 |
2024-12-11 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
CA3243517A1
(en)
|
2022-02-02 |
2023-08-10 |
Akouos, Inc. |
Anti-VEGF Antibody Constructions and Related Methods for the Treatment of Symptoms Associated with Acoustic Neuroma
|
|
WO2023154693A1
(en)
|
2022-02-08 |
2023-08-17 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
AU2023220128A1
(en)
|
2022-02-17 |
2024-08-22 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
|
WO2023156530A1
(en)
|
2022-02-17 |
2023-08-24 |
Lysogene |
Gene therapy for neurodegenerative diseases
|
|
WO2023172926A1
(en)
|
2022-03-08 |
2023-09-14 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exons for treatment of duchenne muscular dystrophy
|
|
EP4490292A1
(en)
|
2022-03-08 |
2025-01-15 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exon 44, 50, and 53 for treatment of duchenne muscular dystrophy
|
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
|
EP4493226A1
(en)
|
2022-03-13 |
2025-01-22 |
RegenxBio Inc. |
Modified muscle-specific promoters
|
|
US20250213727A1
(en)
|
2022-03-25 |
2025-07-03 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
|
EP4504950A1
(en)
|
2022-04-01 |
2025-02-12 |
Takeda Pharmaceutical Company Limited |
Gene therapy for diseases with cns manifestations
|
|
CN119317645A
(zh)
|
2022-04-06 |
2025-01-14 |
宾夕法尼亚州大学信托人 |
用于治疗her2阳性转移性乳腺癌及其他癌症的组合物和方法
|
|
WO2023196851A1
(en)
|
2022-04-06 |
2023-10-12 |
President And Fellows Of Harvard College |
Reversing aging of the central nervous system
|
|
CN119234040A
(zh)
|
2022-04-06 |
2024-12-31 |
建新公司 |
Dm-1肌强直性营养不良的靶向基因疗法
|
|
TW202345913A
(zh)
|
2022-04-06 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如凝膠調配物
|
|
TW202404651A
(zh)
|
2022-04-06 |
2024-02-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如形成聚集體之調配物
|
|
WO2023196892A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
|
|
CA3247507A1
(en)
|
2022-04-06 |
2023-10-12 |
Regenxbio Inc. |
PHARMACEUTICAL COMPOSITION COMPRISING A RECOMMENDED ADENO-ASSOCIATED VIRUS (AAV) VECTOR WITH AN EXPRESSION CASSETTE ENCODED BY A TRANSGENE FOR SUPRACHOROID ADMINISTRATION
|
|
JP2025513835A
(ja)
|
2022-04-11 |
2025-04-30 |
サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック |
化学修飾型アデノ随伴ウイルス
|
|
EP4508062A1
(en)
|
2022-04-11 |
2025-02-19 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
|
KR20250005214A
(ko)
|
2022-04-13 |
2025-01-09 |
우니버시타트 아우토노마 데 바르셀로나 |
클로토 단백질을 발현시키는 유전자 요법을 통한 신경근 질환의 치료
|
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
|
EP4507741A1
(en)
|
2022-04-14 |
2025-02-19 |
RegenxBio Inc. |
Gene therapy for treating an ocular disease
|
|
CA3249261A1
(en)
|
2022-04-18 |
2023-10-26 |
Vertex Pharmaceuticals Incorporated |
COMPOSITIONS AND PROCESSES TO IMPROVE ADENE-ASSOCIATED VIRUS (AAV) THERAPY AND REDUCE AAV TROPISM TO THE LIVER
|
|
US20250288697A1
(en)
|
2022-05-03 |
2025-09-18 |
Regenxbio Inc. |
Vectorized anti-tnf-alpha inhibitors for ocular indications
|
|
TW202400803A
(zh)
|
2022-05-03 |
2024-01-01 |
美商銳進科斯生物股份有限公司 |
載體化抗補體抗體與補體劑及其投與
|
|
CA3255627A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
NEW VP2 FUSION POLYPEPTIDES OF RECOMBINANT AAV
|
|
AR129441A1
(es)
|
2022-05-25 |
2024-08-28 |
Tafalgie Therapeutics |
Péptidos y métodos para el tratamiento del dolor
|
|
WO2023239627A2
(en)
|
2022-06-08 |
2023-12-14 |
Regenxbio Inc. |
Methods for recombinant aav production
|
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
|
EP4544051A2
(en)
|
2022-06-24 |
2025-04-30 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
|
WO2024006770A1
(en)
*
|
2022-06-27 |
2024-01-04 |
Astellas Gene Therapies, Inc. |
Compositions and methods for the treatment of myotonic dystrophies
|
|
TW202417467A
(zh)
|
2022-06-28 |
2024-05-01 |
美商航海家醫療公司 |
Ａａｖ蛋白殼變異體及其用途
|
|
CA3259982A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS
|
|
AR129843A1
(es)
|
2022-07-06 |
2024-10-02 |
Voyager Therapeutics Inc |
Variantes de la cápside de aav y usos de estas
|
|
CA3261865A1
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
TARGETED TRANSCRIPTIONAL ACTIVATION COMPOSITIONS, SYSTEMS AND METHODS
|
|
WO2024020352A1
(en)
|
2022-07-18 |
2024-01-25 |
Vertex Pharmaceuticals Incorporated |
Tandem guide rnas (tg-rnas) and their use in genome editing
|
|
EP4558149A1
(en)
|
2022-07-21 |
2025-05-28 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
|
CN115354049A
(zh)
*
|
2022-07-29 |
2022-11-18 |
中国科学院深圳先进技术研究院 |
一种基因递送系统在将目的基因经静脉注射递送至肝脏的应用
|
|
US20260055144A1
(en)
|
2022-08-24 |
2026-02-26 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
TW202413648A
(zh)
|
2022-08-25 |
2024-04-01 |
日商武田藥品工業股份有限公司 |
用於治療法布立氏病（ｆａｂｒｙ ｄｉｓｅａｓｅ）之組合物及方法
|
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
|
TW202421788A
(zh)
|
2022-09-22 |
2024-06-01 |
美商拜奧馬林製藥公司 |
用ａａｖ基因療法載體治療致心律不整性心肌病
|
|
TW202417631A
(zh)
|
2022-09-22 |
2024-05-01 |
美商拜奧馬林製藥公司 |
用ａａｖ基因治療載體治療心肌病
|
|
US20260034250A1
(en)
|
2022-09-30 |
2026-02-05 |
Regenxbio Inc. |
Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab
|
|
WO2024081746A2
(en)
|
2022-10-11 |
2024-04-18 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
|
WO2024105638A1
(en)
|
2022-11-18 |
2024-05-23 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of hunter syndrome
|
|
WO2024130070A2
(en)
|
2022-12-17 |
2024-06-20 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
|
|
KR20250135916A
(ko)
|
2022-12-17 |
2025-09-15 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
심장 및 골격근 특이적 표적화 모티프를 갖는 재조합 aav 돌연변이체 벡터 및 이를 포함하는 조성물
|
|
IT202200026595A1
(it)
|
2022-12-22 |
2024-06-22 |
Fond Telethon Ets |
Nuovi inibitori di regolatori epigenetici
|
|
WO2024146935A1
(en)
|
2023-01-06 |
2024-07-11 |
Institut National de la Santé et de la Recherche Médicale |
Intravenous administration of antisense oligonucleotides for the treatment of pain
|
|
US12252518B2
(en)
|
2023-01-06 |
2025-03-18 |
Life Biosciences, Inc. |
Methods of treating non-arteritic anterior ischemic optic neuropathy
|
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|
|
JP2026504074A
(ja)
|
2023-01-12 |
2026-02-03 |
ナント・ユニヴェルシテ |
化学修飾されたアデノ随伴ウイルス
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
WO2024163012A1
(en)
|
2023-02-02 |
2024-08-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
|
|
CN121195072A
(zh)
|
2023-02-03 |
2025-12-23 |
詹森药业有限公司 |
用于帕金森病的基因治疗载体
|
|
GB202302480D0
(en)
|
2023-02-22 |
2023-04-05 |
Drishti Discoveries Ltd |
shRNA for the treatment of disease
|
|
CN116286988A
(zh)
*
|
2023-03-03 |
2023-06-23 |
西咸新区沣厚原创医药科技有限公司 |
一种稳定表达冠状病毒3cl蛋白酶的腺相关病毒体系、动物模型及构建方法和应用
|
|
WO2024192281A2
(en)
|
2023-03-15 |
2024-09-19 |
Regenxbio Inc. |
Exon skipping gene therapy constructs, vectors and uses thereof
|
|
WO2024196855A2
(en)
|
2023-03-17 |
2024-09-26 |
University Of Rochester |
Ribozyme-mediated rna assembly and expression
|
|
WO2024211780A1
(en)
|
2023-04-07 |
2024-10-10 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2024215653A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Guide rnas, vectors, and virions for targeting mutations in the pln gene
|
|
WO2024215655A1
(en)
|
2023-04-10 |
2024-10-17 |
Tenaya Therapeutics, Inc. |
Cardioprotective bag3 therapies
|
|
WO2024216244A2
(en)
|
2023-04-13 |
2024-10-17 |
Regenxbio Inc. |
Targeting aav capsids, methods of manufacturing and using same
|
|
CN116622908B
(zh)
*
|
2023-04-13 |
2024-02-06 |
武汉珈创生物技术股份有限公司 |
快速检测野生型腺相关病毒的引物探针、试剂盒及方法和应用
|
|
TW202509211A
(zh)
|
2023-04-26 |
2025-03-01 |
法商賽諾菲公司 |
宿主細胞系以及鑑定和使用該等宿主細胞系之方法
|
|
WO2024228938A1
(en)
*
|
2023-05-01 |
2024-11-07 |
St. Jude Children's Research Hospital, Inc. |
Modified aav p5 promoter for improved vector titer and purity
|
|
EP4704867A1
(en)
|
2023-05-03 |
2026-03-11 |
Sana Biotechnology, Inc. |
Methods of dosing and administration of engineered islet cells
|
|
CN121399470A
(zh)
|
2023-05-03 |
2026-01-23 |
马尼福尔德生物技术有限公司 |
用于高通量蛋白质递送、筛选和检测的方法和组合物
|
|
WO2024233529A2
(en)
|
2023-05-07 |
2024-11-14 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
EP4709406A2
(en)
|
2023-05-11 |
2026-03-18 |
University Hospitals Cleveland Medical Center |
Anxiolytic therapy
|
|
WO2024233791A1
(en)
|
2023-05-11 |
2024-11-14 |
Seelos Therapeutics, Inc. |
Methods of treating neurodegenerative disorders
|
|
AU2024271004A1
(en)
|
2023-05-16 |
2026-01-15 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and administration thereof
|
|
WO2024238859A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Vectorized c5 inhibitor agents and administration thereof
|
|
WO2024238853A1
(en)
|
2023-05-16 |
2024-11-21 |
Regenxbio Inc. |
Adeno-associated viruses for ocular delivery of gene therapy
|
|
WO2024243236A2
(en)
|
2023-05-22 |
2024-11-28 |
Sana Biotechnology, Inc. |
Methods of delivery of islet cells and related methods
|
|
WO2024241176A1
(en)
|
2023-05-24 |
2024-11-28 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of diseases with central nervous system disorders
|
|
CN121358869A
(zh)
|
2023-05-25 |
2026-01-16 |
朱诺治疗学股份有限公司 |
Aav纯化方法
|
|
WO2024258961A1
(en)
|
2023-06-12 |
2024-12-19 |
The Trustees Of The University Of Pennsylvania |
Aav gene therapy for mucopolysaccharidosis iiib
|
|
TW202516019A
(zh)
|
2023-06-29 |
2025-04-16 |
賓州大學委員會 |
具中樞神經系統靶向模體的突變aav及含有其之組成物
|
|
WO2025008406A1
(en)
|
2023-07-04 |
2025-01-09 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of cancer
|
|
WO2025017168A1
(en)
|
2023-07-19 |
2025-01-23 |
Genethon |
Novel optimized utrophin micro-genes
|
|
WO2025017169A1
(en)
|
2023-07-20 |
2025-01-23 |
Genethon |
Novel mididystrophins
|
|
WO2025035143A1
(en)
|
2023-08-10 |
2025-02-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of spinal muscular atrophy
|
|
WO2025038430A1
(en)
|
2023-08-16 |
2025-02-20 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
WO2025072604A1
(en)
|
2023-09-28 |
2025-04-03 |
University Of Rochester |
Rna-editing gene therapy approaches for treating myotonic dystrophy type 1 (dm1)
|
|
WO2025075963A1
(en)
|
2023-10-02 |
2025-04-10 |
Regenxbio Inc. |
Methods and formulations for treating mucopolysaccharidosis ii-associated hearing loss with recombinant human iduronate-2-sulfatase
|
|
WO2025080780A1
(en)
|
2023-10-10 |
2025-04-17 |
University Of Rochester |
Delivery and expression of prime editing crispr systems
|
|
WO2025090962A1
(en)
|
2023-10-25 |
2025-05-01 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
|
WO2025090858A1
(en)
|
2023-10-27 |
2025-05-01 |
Biogen Ma Inc. |
Methods for identifying aav capsid variants with desired characteristics
|
|
WO2025102034A1
(en)
|
2023-11-10 |
2025-05-15 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for barth syndrome
|
|
WO2025106374A1
(en)
|
2023-11-13 |
2025-05-22 |
Juno Therapeutics, Inc. |
Aav production method
|
|
WO2025106661A1
(en)
|
2023-11-14 |
2025-05-22 |
The Trustees Of The University Of Pennsylvania |
Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof
|
|
WO2025108407A2
(en)
|
2023-11-23 |
2025-05-30 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Gene therapy compositions and methods for treating glioma
|
|
WO2025113676A1
(en)
|
2023-11-29 |
2025-06-05 |
Neuexcell Therapeutics (Suzhou) Co., Ltd. |
Compositions and methods for treating stroke in primates
|
|
WO2025128817A1
(en)
|
2023-12-15 |
2025-06-19 |
Genzyme Corporation |
Artificial micrornas targeting tau
|
|
WO2025129157A1
(en)
|
2023-12-15 |
2025-06-19 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treatment of canavan disease
|
|
WO2025137219A1
(en)
|
2023-12-21 |
2025-06-26 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of disorders related to dystrophia myotonica protein kinase
|
|
WO2025147436A1
(en)
|
2024-01-03 |
2025-07-10 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
|
TW202548014A
(zh)
|
2024-01-26 |
2025-12-16 |
美商健臻公司 |
靶向亨丁頓舞蹈症之人工ｍｉｃｒｏｒｎａ
|
|
WO2025160429A1
(en)
|
2024-01-26 |
2025-07-31 |
Genzyme Corporation |
Artificial micrornas targeting snca
|
|
WO2025179007A1
(en)
*
|
2024-02-21 |
2025-08-28 |
The Regents Of The University Of California |
Adeno-associated virus compositions and methods of use thereof for human cells
|
|
TW202548022A
(zh)
|
2024-03-03 |
2025-12-16 |
美商帕西奇生物公司 |
用於治療神經退化性病症之重組腺相關病毒
|
|
WO2025217214A2
(en)
|
2024-04-08 |
2025-10-16 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
|
TW202548025A
(zh)
|
2024-04-08 |
2025-12-16 |
美商銳進科斯生物股份有限公司 |
載體化抗補體抗體與補體劑及其投與
|
|
WO2025214477A1
(en)
|
2024-04-12 |
2025-10-16 |
Skyline Therapeutics (Shanghai) Co., Ltd. |
Treatment of genetic cardiomyopathies with aav gene therapy vectors
|
|
CN118459608B
(zh)
*
|
2024-04-26 |
2025-01-24 |
泰州博莱得利生物科技有限公司 |
犬细小病毒特异性免疫制剂、制备方法和应用
|
|
WO2025237990A1
(en)
|
2024-05-14 |
2025-11-20 |
Institut National de la Santé et de la Recherche Médicale |
Antisense oligonucleotides and their use for the treatment of pulmonary fibrosis
|
|
WO2026006341A1
(en)
|
2024-06-24 |
2026-01-02 |
Regenxbio Inc. |
Microdystrophin gene therapy administration for treatment of dystrophinopathies
|
|
CN118460614B
(zh)
*
|
2024-07-05 |
2025-03-11 |
凌意(杭州)生物科技有限公司 |
一种腺相关病毒Cap蛋白的表达框
|
|
WO2026035687A1
(en)
|
2024-08-05 |
2026-02-12 |
University Of Rochester |
Compositions and methods for stitchr-mediated full-length scn5a expression in vivo
|
|
WO2026055342A1
(en)
|
2024-09-04 |
2026-03-12 |
Arsenal Biosciences, Inc. |
Synthetic pathway activators
|
|
CN120249230B
(zh)
*
|
2025-06-05 |
2025-11-07 |
鼐济医药科技(杭州)有限公司 |
一种用于同时生产多种重组腺相关病毒的方法
|
|
CN121142059B
(zh)
*
|
2025-11-17 |
2026-02-17 |
吉林农业大学 |
一种基于dia质谱技术评估微塑料神经毒性的方法及系统
|